drugset
drugset / Trial / NCT01319916

Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue

NCT01319916 ↗

Phase 1 Completed 10 enrolled Kythera Biopharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

Open Label Study to Evaluate the Serum Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 into Abdominal Fat Tissue

Timeline

Start
2010-12
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ATX-101 Peptide 2 unknown Subcutaneous

Indications

No indication recorded.